medigraphic.com

2013, Number 6

<< Back Next >>

Cir Cir 2013; 81 (6)

Molecular classification of breast cancer: relationship with clinicopathological characteristics and histological grade in women of northwestern Mexico

Ornelas-Aguirre JM, Pérez-Michel JMA

Language: Spanish
References: 42
Page: 496-507
PDF size: 633.70 Kb.


ABSTRACT

Background: Breast cancer is a heterogeneous disease with molecular subtypes that vary in their etiology. In his diagnosis, pathologists performed a semi-quantitative analysis of morphological characteristics to determine the histologic grade of tumor.
Objective: To analyze the immunohistochemistry molecular expression profile in breast cancer adjusted for clinical and histopathological variables and their impact on recurrence and disease-free survival.
Methods: Of 768 women with breast carcinoma, in 596 (77.60%) were defined 5 immunohistochemistry profiles (luminal A, luminal B, mixed, HER2/neu and triple negative). We analyzed whether there were differences between them in relation to clinical and histopathological variables adjusted for histologic grade.
Results: Of 596 cases, 201 (33.72%) were luminal A, 40 (6.71%) luminal B, 77 (12.91%) mixed, 108 (18.12%) HER2/neu and 170 (28.52%) triple negative. The age and stage greater than III were associated with intrinsic subtypes of breast cancer (p= 0.04), and the persistence of the disease in triple negative so borderline (p= 0.09). The luminal B subtype was associated with poor prognosis for recurrence (LR= 5.991, p= 0.014) with univariate analysis. Multivariate analysis found an association for increased risk of death in HER2/neu positive subtype (LR= 7.193, p= 0.007) and mixed (LR= 5.191, p= 0.023), and the application of radiotherapy was revealed as a protective factor (LR= 0.678, p= 0.001).
Conclusion: This study demonstrates that Scarff-Bloom- Richardson histologic grade is an independent prognostic factor that correlates with biomarkers for the development and monitoring of breast carcinoma.


REFERENCES

  1. Bloom HJG, Richardson WW. Histological Grading and Prognosis in Breast Cancer. A Study of 1409 Cases of which 359 have been Followed for 15 Years. Br J Cancer. 1957;11(3):359-377.

  2. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-410.

  3. Greenough RB. Varying Degrees of Malignancy in Cancer of the Breast. J. Cancer Res. 1925;9:452-463.

  4. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic Factors in Breast Cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):966-978.

  5. Gao F, Carter G, Tseng G, Chivukula M. Clinical Importance of Histologic grading of Lobular Carcinoma in situ (LCIS) in Breast Core Needle Biopsy Specimens. Am J Clin Pathol. 2010;133:767- 771.

  6. Lundin J, Lundin M, Holli K, Kataja V, Elomaa L, Pylkkänen L, et al. Omission of Histologic Grading From Clinical Decision Making May Result in Overuse of Adjuvant Therapies in Breast Cancer: Results From a Nationwide Study. J Clin Oncol. 2001;19(1):28-36.

  7. Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology. 1995;27(3):219-226.

  8. Rakha EA, El-Sayed ME, Lee AHS, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma. J Clin Oncol. 2008;26(19):3153-3158.

  9. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 1986;58(12):2662-2670.

  10. Otsuki Y, Shimizu S, Suwa K, Yoshida M, Kanzaki M, Kobayashi H. Which is Better Pathological Prognostic Factor, the Nottingham Histological Grade or the Japanese Nuclear Grade? A Large Scale Study with a Long-term Follow-up. Jpn J Clin Oncol. 2007;37(4):266-274.

  11. Chen ST, Lai HW, Tseng HS, Chen LS, Kuo SJ, Chen DR. Correlation of Histologic Grade With Other Clinicopathological Parameters, Intrinsic Subtype, and Patients’ Clinical Outcome in Taiwanese Women. Jpn J Clin Oncol. 2011;41(12):1327-1335.

  12. Beck AH, Sangoi AR, Leung S, Marinelli RJ, Nielsen TO, van de Vijver MJ, et al. Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival. Sci Transl Med. 2011;3(108):108ra-113.

  13. Wishart GC, Bajdik CD, Azzato EM, Dicks E, Greenberg DC, Rashbass J, et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur J Surg Oncol. 2011;37(5):411-417.

  14. Tambasco M, Eliasziw M, Magliocco AM. Morphologic complexity of epithelial architecture for predicting invasive breast cancer survival. J Transl Med. 2010;8:140.

  15. Gerson R, Alban F, Villalobos A, Serrano A. Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype. Gac Med Mex. 2008;144(1):27-34.

  16. Cortés-Flores AO, Morgan-Villela G, Castro-Cervantes JM, Vázquez-Camacho G, Fuentes-Orozco C, González-Ojeda A. Tratamiento neoadyuvante del cáncer de mama localmente avanzado. Comparación de dos esquemas a base de docetaxel-epirubicina versus 5-fluorouracilo-epirubicina-cyclophosphamida. Cir Ciruj. 2008;76(1):23-28.

  17. Ocón Hernández O, Fernández Cabrera MF, Pérez Vicente S, Dávila Arias C, Expósito Hernández J, Olea Serrano N. Breast cancer survival after 10 years of follow up, in Granada and Almeria Spanish Provinces. Rev Esp Salud Publica. 2010;84(6):705-715.

  18. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117(16):3658-3669.

  19. Chou SE, Huang CY, Sheen-Chen SM, Liu YW, Tsai CH, Lin YH, et al. An Evaluation of Prognostic Value of Death-associated Protein Kinase 1 in Breast Cancer. Anticancer Res. 2011;31(10):3633-3636.

  20. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype. Clin Cancer Res. 2008;14(5):1368-1376.

  21. Park YH, Lee SJ, Cho EY, Choi YL, Lee JE, Nam SJ, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol. 2011;22(7):1554-1560.

  22. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, et al. Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients. Clin Cancer Res. 2009;15(12):4181-4190.

  23. Slanger TE, Chang-Claude JC, Obi N, Kropp S, Berger J, Vettorazzi E, et al. Menopausal Hormone Therapy and Risk of Clinical Breast Cancer Subtypes. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1188-1196.

  24. Nouh M, Ismail H, El-Din NH, El-Bolkainy MN. Lymph node metastasis in breast carcinoma: clinicopathological correlations in 3747 patients. J Egypt Natl Canc Inst. 2004;16(1):50-56.

  25. Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, Boyd JC, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol. 1995;103(2):195- 198.

  26. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: A study of interobserver agreement. Hum Pathol. 1995;26(8):873-879.

  27. Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR & HER-2/neu (C-erb B 2) Reactivity Pattern with Histologic Grade, Tumor Size and Lymph Node Status in Breast Cancer. Asian Pac J Cancer Prev. 2008;9(4):553-556.

  28. Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002;52(3):186-194.

  29. Barnes DM, Hanby AM. Oestrogen and progesterone receptors in breast cancer: past, present and future. Histopathology. 2001;38(3):271-274.

  30. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade to Improve Prognosis. J Natl Cancer Inst. 2006;98(4):262-272.

  31. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, et al. Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer. J Clin Oncol. 2009;27(19):3185-3191.

  32. McGuire WL, Clark GM. The prognostic role of progesterone receptors in human breast cancer. Semin Oncol. 1983;10(4 Suppl 4):2-6.

  33. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol. 1999;26(4 Suppl 12):51-59.

  34. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991;63(3):439-443.

  35. Suo Z, Risberg B, Karlsson MG, Villman K, Skovlund E, Nesland JM. The Expression of EGFR Family Ligands in Breast Carcinomas. Int J Surg Pathol. 2002;10(2):91-99.

  36. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.

  37. Zeillinger R, Kury F, Czerwenka K, Kubista E, Sliutz G, Knogler W, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 1989;4(1):109-114.

  38. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.

  39. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsec Subtypes. J Clin Oncol. 2009;27(8):1160-1167.

  40. Park HS, Kim S, Kim K, Yoo H, Chae BJ, Bae JS, et al. Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer. World J Surg Oncol. 2012;10:4.

  41. Piñero-Madrona A, Polo-García L, Alonso-Romero JL, Salinas- Ramos J, Canteras-Jordana M, Sola-Pérez J, et al. Características inmunohistoquímicas del cáncer de mama: ¿hacia una nueva clasificación? Cir Esp. 2008;84(3):138-145.

  42. Irigoyen MA, García FV, Iturriagagoitia AC, Beroiz BI, Martínez MS, Grima FG. Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics. An Sist Sanit Navar. 2011;34(2):219-233.




2020     |     www.medigraphic.com